Macquarie Group Ltd. acquired a new position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $316,000.

Other hedge funds also recently added to or reduced their stakes in the company. Argent Capital Management LLC bought a new position in Eagle Pharmaceuticals during the second quarter worth $686,000. Russell Investments Group Ltd. lifted its holdings in shares of Eagle Pharmaceuticals by 7,357.0% during the second quarter. Russell Investments Group Ltd. now owns 46,084 shares of the specialty pharmaceutical company’s stock worth $3,634,000 after buying an additional 45,466 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of Eagle Pharmaceuticals by 7.2% during the second quarter. Blair William & Co. IL now owns 79,035 shares of the specialty pharmaceutical company’s stock worth $6,235,000 after buying an additional 5,340 shares in the last quarter. Advisory Services Network LLC lifted its holdings in shares of Eagle Pharmaceuticals by 52.8% during the second quarter. Advisory Services Network LLC now owns 12,225 shares of the specialty pharmaceutical company’s stock worth $964,000 after buying an additional 4,225 shares in the last quarter. Finally, U S Global Investors Inc. acquired a new stake in shares of Eagle Pharmaceuticals during the second quarter worth $1,097,000.

Shares of Eagle Pharmaceuticals, Inc. (EGRX) opened at $57.40 on Monday. Eagle Pharmaceuticals, Inc. has a twelve month low of $45.05 and a twelve month high of $97.15. The company has a current ratio of 5.30, a quick ratio of 5.15 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $856.52, a price-to-earnings ratio of 9.05 and a beta of 1.24.

EGRX has been the subject of a number of research reports. Piper Jaffray Companies reissued a “buy” rating and set a $75.00 target price on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. Royal Bank of Canada reissued an “outperform” rating and set a $75.00 target price (down previously from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. ValuEngine downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Finally, Mizuho reissued a “sell” rating and set a $37.00 target price on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Eagle Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $62.33.

TRADEMARK VIOLATION WARNING: “Macquarie Group Ltd. Acquires Shares of 5,300 Eagle Pharmaceuticals, Inc. (EGRX)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/macquarie-group-ltd-acquires-shares-of-5300-eagle-pharmaceuticals-inc-egrx/1770612.html.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.